January 2024 - Page 2 of 17

TuesdayJan 30, 2024 12:50 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Submission of IND for Planned Phase 1b Hypertension Trial

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has submitted its much-anticipated Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”). The application covers HYPER-H23-1, the company’s upcoming planned U.S. phase 1b hypertension clinical trial of DehydraTECH-CBD. According to the announcement, the company had a successful pre-IND meeting with FDA officials. Following the guidance provided in that meeting regarding the development and filing of the IND, the company submitted the application on Jan. 29, 2024. The company will now wait 30 calendar days before initiating any clinical trials, in compliance with FDA guidelines.…

TuesdayJan 30, 2024 12:16 pm

QualityStocksNewsBreaks — SOBR Safe Inc. (NASDAQ: SOBR) Expands Sales of Wearable Alcohol Detection Devices to Australia, New Zealand

SOBRSafe (NASDAQ: SOBR), providers of next-generation transdermal alcohol detection solutions, has entered into an international channel partnership to begin sales in Australia and New Zealand for its SOBRsure(TM) platform. The partnership is with Drug Testing Business Success, the region's leading drug- and alcohol-testing service provider. According to the announcement, Drug Testing Business Success has impressive experience in the transdermal alcohol detection industry and plans to distribute SOBRsure through a coalition of suppliers and a dedicated e-commerce website focusing on the behavioral health and justice sectors. The partnership included a 90-day proof-of-concept period; SOBRsure is now available for sale and is in…

TuesdayJan 30, 2024 10:07 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Information on $4M Public Offering Pricing

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced the pricing of its public offering. According to the announcement, the “reasonable best efforts” public offering involves participation from healthcare-focused institutional investors and certain officers and directors of the company. The offering is comprised of the purchase and sale of 13,333,334 shares of common stock (or common stock equivalents in lieu thereof); the stock is offered at a purchase price of $0.30 per share. In addition, CNSP agreed to issue Series A warrants…

TuesdayJan 30, 2024 9:45 am

Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FRA: GDT0) Suite Shows Importance Amidst Reports of Latest Microsoft Corporation Cybersecurity Attack

Cyber attacks can cost corporations millions of dollars, endangering critical sensitive information, causing major operational headaches, and affecting hard-won corporate reputations Microsoft recently announced detection of a cyberattack that compromised the company’s corporate emails – an attack found to be launched by a Russian state-sponsored group referred to as Midnight Blizzard Sekur Private Data Ltd. offers consumers, businesses, corporations, and governments, Swiss-hosted solutions for secure communications and secure data management without the use of third-party cloud services Cybersecurity attacks can cost corporations more than significant amounts of money – they can come with hidden costs like an increase in insurance…

TuesdayJan 30, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Unites Physics, Chemistry, Material Science, and Biology to Address Neurodegenerative Diseases With The Company’s Unique CNM-Au8(R) Pipeline

An innovative combination of insights from physics, chemistry, materials science, and biology positions the new nanomedicine CNM-Au8(R) to address neurodegenerative disease, such as ALS, from a new angle The FDA has offered guidance to Clene on CNM-Au8’s application, with discussions ongoing for the possibility of accelerated approval on the basis of improved survival, biomarker, and clinical efficacy data in people living with ALS With plans to move forward on many fronts for the clinical development of CNM-Au8, 2024 looks bright for Clene Clene (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function…

MondayJan 29, 2024 12:39 pm

QualityStocksNewsBreaks — SenesTech Inc. (NASDAQ: SNES) Inks Grain-Management Distribution Agreement with Poppe Enterprises

SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal-pest populations, has entered a signed distribution agreement with Poppe Enterprises LLC. A distributor and pest-management company focused on the grain-management market, Poppe Enterprises serves Nebraska, South Dakota, North Dakota, Kansas, Wyoming, Iowa and Colorado. Poppe Enterprises will be a stocking distributor for SNES’s Evolve(TM) soft bait and has placed an initial stocking order. Evolve is designed to address the fundamental issue of rodent overpopulation by focusing on the rapid reproduction of rats; the product controls the population by reducing or eliminating the fertility of rats, rather than trying to keep up with the…

MondayJan 29, 2024 12:02 pm

QualityStocksNewsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Class 3 EV Truck Receives CARB Certification

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has reached a commercial electric-vehicle milestone: its all-electric Class 3 low cab forward chassis truck has received certification from the California Air Resources Board (“CARB”), which means the vehicle meets specific emissions standards in compliance with CARB regulations. The certification means the vehicle qualifies for important state incentive programs, including an opportunity with California’s Hybrid and Zero-Emission Truck and Bus Voucher Incentive Project (“HVIP”) project. The HVIP project offers a rebate of up to $45,000 and, when combined with the $7,500 federal tax credit, totals a net effective cost of less than $20,000…

MondayJan 29, 2024 12:00 pm

SOBRsafe Inc. (NASDAQ: SOBR) Announces Partnership with Navix Health Aimed at Enhancing Patient Care and Outcomes

SOBRsafe’s alcohol detection technology can improve behavioral outcomes and help save lives Navix Health, a leading provider of innovative behavioral healthcare support technologies, has chosen SOBRsafe as its exclusive alcohol data partner, integrating SOBRsafe’s transdermal detection solutions into Navix Hub(TM) SOBRsafe’s products include SOBRsafe(TM), SOBRcheck(TM), and SOBRsure(TM) SOBRsafe (NASDAQ: SOBR), a provider of advanced transdermal alcohol detection technology, recently announced that Navix Health, a leading provider of behavioral healthcare support technologies, has chosen SOBRsafe as its exclusive alcohol data partner, integrating the company’s transdermal detection solutions into Navix Hub(TM). With the integration of SOBRsafe into Navix Hub, customers can augment…

MondayJan 29, 2024 11:43 am

QualityStocksNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Granted US Patent Allowance for Key Technology Behind Lead Investigation Product

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, has received notice from the United States Patent and Trademark Office (“USPTO”) of patent allowance for Medicinal Signaling Cells (“MSCs”). The patent covers the technology behind LGVN’s lead investigational product Lomecel-B(TM) and will impact patients with Aging-related Frailty receiving vaccines for conditions such as COVID-19 and the flu. Lomecel-B is a living-cell product made from MSCs that are essential to the body’s endogenous biological repair mechanism and that have been shown to perform complex functions in the body, including the formation of new tissue.…

Site Search

Company Search

Month: January 2024